Amy S. Marren

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
OBJECTIVE Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and maintenance treatment in patients with moderate-to-severe Crohn's disease (CD). DESIGN We conducted two randomised, double-blind, placebo-controlled, multicentre phase IIb(More)
INTRODUCTION Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), and is being investigated for the treatment of psoriasis. Both conditions can present in women of child-bearing potential, but pregnancy was an exclusion and discontinuation criterion in tofacitinib randomized controlled trials (RCTs) because of the(More)
OBJECTIVES To examine treatment patterns, dosing, health care resource utilization, and cost of tumor necrosis factor inhibitors (TNFi), adalimumab (ADA) and infliximab (IFX), among patients enrolled in US Humana insurance plans who have been diagnosed with ulcerative colitis (UC). METHODS This retrospective cohort study identified the first pharmacy or(More)
As the Global Medical Affairs Gastroenterology Lead for tofacitinib at Pfizer, I read with great interest the review by Dr Ungar and Dr Kopylov entitled “Advances in the development of new biologics in inflammatory bowel disease (IBD)” [1]. In reading the article, I identified a number of inaccuracies concerning tofacitinib, which I thought should be(More)
  • 1